Make a gift before the end of the year to drive research breakthroughs in 2026.
By Anna Greene, PhD, NETRF Chief Scientific Officer Drugs like Ozempic®, Wegovy®, and Mounjaro®, known as GLP-1 receptor agonists, are now widely used to treat
By Anna Greene, PhD, NETRF Chief Scientific Officer Each year, the Margie & Robert E. Petersen NETRF Research Symposium brings together leading scientists, clinicians, and
By Udhayvir Singh Grewal, MD, Assistant Professor of Medical Oncology, Emory University School of Medicine Guest Contributor The Annual NANETS Multi-Disciplinary Symposium 2025 was a
Congratulations to Dr. Dawn Quelle, NETRF Board of Scientific Advisors co-chair, and the team at the University of Iowa Health, for winning a $10.7 million
NETRF CEO Elyse Gellerman, Chief Scientific Officer Anna Greene, and Director of Patient Education Jessica Thomas joined hundreds of neuroendocrine cancer specialists and patient advocates
A recent review published in the Journal of Oncology Practice explores how patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) view the use and timing of radioligand
The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) in partnership with NETRF is proud to announce Dr. Carolin Kitzberger of TUM
The early results from a first-in-human clinical trial suggest that a novel copper-based PET imaging agent may deliver clearer and more comprehensive scans for people
Chimeric Therapeutics has reported that a neuroendocrine cancer patient in the Phase 1 clinical trial of CAR T cell therapy has experienced tumor shrinkage. In
By Anna Greene, PhD, NETRF Chief Scientific Officer NETRF-funded scientists uncover how oxygen levels shape tumor behavior and expose new treatment opportunities for pheochromocytomas and